IL153231D0 - Wet milling process - Google Patents

Wet milling process


Publication number
IL153231D0 IL15323101A IL15323101A IL153231D0 IL 153231 D0 IL153231 D0 IL 153231D0 IL 15323101 A IL15323101 A IL 15323101A IL 15323101 A IL15323101 A IL 15323101A IL 153231 D0 IL153231 D0 IL 153231D0
Prior art keywords
wet milling
drug substance
milling process
Prior art date
Application number
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0015856A priority Critical patent/GB0015856D0/en
Priority to GB0112496A priority patent/GB0112496D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to PCT/EP2001/007085 priority patent/WO2002000196A2/en
Publication of IL153231D0 publication Critical patent/IL153231D0/en



A process for preparing a finely divided preparation of a drug substance comprising wet milling a suspension of the drug substance in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising nylon, wherein the nylon comprises one or more internal lubricants results in finely divided preparations of a drug substance in which the level of grinding media contamination and process contamination are reduced.
IL15323101A 2000-06-28 2001-06-22 Wet milling process IL153231D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0015856A GB0015856D0 (en) 2000-06-28 2000-06-28 Wet milling process
GB0112496A GB0112496D0 (en) 2001-05-22 2001-05-22 Wet milling process
PCT/EP2001/007085 WO2002000196A2 (en) 2000-06-28 2001-06-22 Wet milling process

Publications (1)

Publication Number Publication Date
IL153231D0 true IL153231D0 (en) 2003-07-06



Family Applications (2)

Application Number Title Priority Date Filing Date
IL15323101A IL153231D0 (en) 2000-06-28 2001-06-22 Wet milling process
IL15323102A IL153231A (en) 2000-06-28 2002-12-02 Wet milling process

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15323102A IL153231A (en) 2000-06-28 2002-12-02 Wet milling process

Country Status (25)

Country Link
US (2) US20040089753A1 (en)
EP (1) EP1294358B1 (en)
JP (1) JP4188078B2 (en)
KR (1) KR100786927B1 (en)
CN (1) CN1321628C (en)
AR (1) AR029284A1 (en)
AT (1) AT273695T (en)
AU (2) AU2002215608B2 (en)
BR (1) BR0111747A (en)
CA (1) CA2413330A1 (en)
CZ (1) CZ303572B6 (en)
DE (1) DE60105023T2 (en)
ES (1) ES2225624T3 (en)
HK (1) HK1055242A1 (en)
HU (1) HU230396B1 (en)
IL (2) IL153231D0 (en)
MX (1) MXPA03000051A (en)
MY (1) MY128806A (en)
NO (1) NO333747B1 (en)
NZ (1) NZ522783A (en)
PL (1) PL202623B1 (en)
PT (1) PT1294358E (en)
SI (1) SI1294358T1 (en)
TW (1) TWI290836B (en)
WO (1) WO2002000196A2 (en)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006132B1 (en) * 2000-10-20 2005-10-27 Биовитрум Аб 2-, 3-, 4- or 5-substituted-n- (1- (aryl, heteroaryl or arylalkyl) sulfonyl) indoles and their use in therapy
GB0112497D0 (en) * 2001-05-22 2001-07-11 Smithkline Beecham Plc Formulation
GB0206200D0 (en) * 2002-03-15 2002-05-01 Glaxo Group Ltd Pharmaceutical compositions
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd compounds
US7140567B1 (en) * 2003-03-11 2006-11-28 Primet Precision Materials, Inc. Multi-carbide material manufacture and use as grinding media
CA2530044C (en) 2003-06-17 2012-09-25 Phibro-Tech, Inc. Particulate wood preservative and method for producing same
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
AT450535T (en) 2003-09-03 2009-12-15 Glaxo Group Ltd New process for production of pleuromutilinderivaten
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
US7578455B2 (en) * 2004-08-09 2009-08-25 General Motors Corporation Method of grinding particulate material
EP2431430B1 (en) 2004-10-14 2017-02-01 Koppers Performance Chemicals Inc. The use of micronized wood preservative formulations in organic carriers
JPWO2006062238A1 (en) * 2004-12-07 2008-06-12 味の素株式会社 Powder and suspensions thereof amino acids
WO2006091885A2 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
WO2006120541A1 (en) 2005-05-10 2006-11-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ether linked macrolides useful for the treatment of microbial infections
US8034953B2 (en) 2005-05-10 2011-10-11 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
DE102006028590A1 (en) * 2006-06-22 2007-12-27 Forschungszentrum Karlsruhe Gmbh Device for the production of ceramic granulates, comprises mixing-mill-unit consisting of agitation unit and continuously running agitator ball mill, and spray-drying unit that has cyclone separator beneath spraying tower and has condenser
WO2007150026A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
BRPI0713619A2 (en) 2006-06-23 2013-01-15 Incyte Corp compound or prodrug or pharmaceutically acceptable salt thereof, composition, and use of the compound.
US7828543B2 (en) * 2006-07-27 2010-11-09 Casa Herrera, Inc. Dough sheeter cutter roller
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
EP2061459B1 (en) 2006-08-23 2012-12-26 Intellect Neurosciences Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp Compounds derived from n-hydroxyamino heterocycle; A pharmaceutical composition useful for treating cancer, viral infections, and neurodegenerative disorders, among others.
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
ES2415863T3 (en) 2006-12-22 2013-07-29 Incyte Corporation Substituted heterocycles as Janus Kinase inhibitors
US7883039B2 (en) * 2007-02-27 2011-02-08 Collette Nv Continuous granulating and drying apparatus including measurement units
JP2008235481A (en) * 2007-03-19 2008-10-02 Nippon Chem Ind Co Ltd Semiconductor wafer polishing composition, manufacturing method thereof, and polishing processing method
EP2173752B1 (en) 2007-06-13 2014-03-19 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp derivatives pyrrolo [2,3-b] pyrimidine, modulators JAK kinases; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
ES2531056T3 (en) 2007-06-21 2015-03-10 Incyte Corp Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
PL2178858T3 (en) 2007-08-02 2012-07-31 Novel heterocyclic compounds as mglu5 antagonists
EA020777B1 (en) 2007-11-16 2015-01-30 Инсайт Корпорейшн Pyrazolyl-4-n-arilpirimidin-2-amine, 4-pyrazolyl-n-pirazolilpirimidin-2-amines and 4-pyrazolyl-n-piridilpirimidin-2-amines as janus kinase inhibitors
JP5275371B2 (en) 2008-03-11 2013-08-28 インサイト・コーポレイションIncyte Corporation Azetidine derivatives and cyclobutane derivatives as JAK inhibitors
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
LT2300455T (en) 2008-05-21 2017-11-10 Incyte Holdings Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010090680A1 (en) 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
WO2010077839A1 (en) 2008-12-15 2010-07-08 Wyeth Llc (Formerly Known As Wyeth) Substituted oxindol cb2 agonists for pain treatment
WO2010075270A1 (en) 2008-12-22 2010-07-01 Incyte Corporation 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators
WO2010082018A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US20110294901A1 (en) * 2009-01-30 2011-12-01 Shigeru Chikase Finely pulverized pharmaceutical composition
CA2789164A1 (en) 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
EP2393780A1 (en) 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
JP5731407B2 (en) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド Actagardine derivatives
EP2396004A4 (en) 2009-02-11 2012-07-25 Reaction Biology Corp Selective kinase inhibitors
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
AR076052A1 (en) 2009-03-20 2011-05-18 Incyte Corp Derivatives of substituted pyrimidines, pharmaceutical compositions containing them and their use in disorders associated with histamine h4, such as inflammatory disorders, pruritus and pain.
JP2013523599A (en) 2009-04-02 2013-06-17 シャイア エルエルシー Novel opioid dicarboxylic acid linked amino acid and peptide prodrugs and uses thereof
EA020494B1 (en) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-YL] octane GEPTANNITRIL OR AS INHIBITORS OF JAK-
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596896A (en) 2009-06-24 2012-07-18 夏尔有限责任公司 Mexiletine amino acid and peptide prodrugs and uses thereof
DK2448938T5 (en) 2009-06-29 2015-10-05 Incyte Corp Pyrimidinones AS PI3K inhibitors
AU2010272233A1 (en) 2009-07-17 2012-02-09 Shire Llc Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
US20110098278A1 (en) 2009-07-23 2011-04-28 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
EP2467362A4 (en) 2009-08-17 2013-06-26 Brigham & Womens Hospital Phosphatidylcholine transfer protein inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2477981A1 (en) 2009-09-14 2012-07-25 Recordati Ireland Limited Heterocyclic mglu5 antagonists
GB0916163D0 (en) 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
KR101805936B1 (en) 2009-10-09 2017-12-07 인사이트 홀딩스 코포레이션 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AR079529A1 (en) 2009-12-18 2012-02-01 Incyte Corp Aryl and heteroaryl derivatives and cast as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US20110207754A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
HUE037077T2 (en) 2010-03-10 2018-08-28 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
MX2013000300A (en) 2010-07-09 2013-02-27 Recordati Ireland Ltd Novel spiroheterocyclic compounds as mglu5 antagonists.
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
BR112013004275A2 (en) 2010-08-24 2016-08-02 Imp Innovations Ltd polypropyleterimine glycodendrimers
WO2012028629A1 (en) 2010-09-02 2012-03-08 Glaxo Group Limited 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
KR20130105655A (en) 2010-09-15 2013-09-25 샤이어 엘엘씨 Prodrugs of guanfacine
WO2012046062A1 (en) 2010-10-05 2012-04-12 Shire, Llc Use of prodrugs to avoid gi mediated adverse events
JP2014504260A (en) * 2010-10-15 2014-02-20 グラクソ グループ リミテッドGlaxo Group Limited Aggregated nanoparticulate drug formulation, its manufacture and use
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US20120196933A1 (en) 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
US9566269B2 (en) 2011-01-20 2017-02-14 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
RU2013140467A (en) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Allocated compounds from turkmen oil and ways of application
US9181375B2 (en) 2011-02-14 2015-11-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fluorescent potassium ion sensors
JP5936628B2 (en) 2011-02-18 2016-06-22 ノバルティス・ファルマ・アクチェンゲゼルシャフトNovartis Pharma AG MTOR / JAK inhibitor combination therapy
MX2013009501A (en) 2011-02-18 2014-02-03 Alixion Pharma Internat S Rl Methods for synthesizing molybdopterin precursor z derivatives.
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CA2839584A1 (en) * 2011-07-07 2013-01-10 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
SI3196202T1 (en) 2011-09-02 2019-05-31 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
BR112014005174A2 (en) 2011-09-07 2017-04-18 Incyte Corp processes and intermediates to make a jak inhibitor
JP6073545B2 (en) * 2011-10-04 2017-02-01 横浜油脂工業株式会社 Lignan-containing fine particles and composition
AR088320A1 (en) 2011-10-14 2014-05-28 Incyte Corp Isoindolinone derivatives and pyrrolopyridinone as inhibitors akt
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas bicyclic inhibitors of PI3K
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9845320B2 (en) 2012-08-29 2017-12-19 Icahn School Of Medicine At Mount Sinai Benzothiazole or benzoxazole compounds as sumo activators
WO2014059314A1 (en) 2012-10-12 2014-04-17 Mayo Foundation For Medical Education And Research Treating brain cancer using agelastatin a (aa) and analogues thereof
TWI646099B (en) 2012-11-01 2019-01-01 英塞特控股公司 As jak inhibitors are tricyclic fused thiophene derivative
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE14482015A1 (en) 2013-01-15 2015-09-28 Incyte Corp Tiazolcarboxamidas compounds and useful as kinase inhibitors pyridinecarboxamide pim
CN105121023B (en) * 2013-02-28 2017-08-25 太阳化学公司 Apparatus and continuous method of making abrasive in a liquid dispersion for solids
BR112015021458A2 (en) 2013-03-06 2017-07-18 Incyte Corp processes and intermediates for preparing a jak inhibitor
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
CA2903881A1 (en) 2013-03-15 2014-09-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
ES2635560T3 (en) 2013-07-08 2017-10-04 Incyte Holdings Corporation Tricyclic heterocycles as NET protein inhibitors
PE02232016A1 (en) 2013-08-07 2016-04-27 Incyte Corp Dosage forms for extended release JAK inhibitor 1
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
PE08632016A1 (en) 2013-11-08 2016-09-03 Incyte Holdings Corp Process for the synthesis of an inhibitor of indoleamine 2,3 dioxygenase
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015081246A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015106240A1 (en) 2014-01-13 2015-07-16 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP2017510555A (en) 2014-02-13 2017-04-13 インサイト・コーポレイションIncyte Corporation Cyclopropylamines as LSD1 inhibitors
MX2016010395A (en) 2014-02-13 2017-02-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors.
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US20150246046A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA201692011A1 (en) 2014-04-08 2017-01-30 Инсайт Корпорейшн Treatment of b-cell malignant nuclear formations with the use of jak and pi3k inhibitors combination
EP3134403A1 (en) 2014-04-23 2017-03-01 Incyte Corporation 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
TW201625641A (en) 2014-05-22 2016-07-16 Genzyme Corp Nampt inhibitors and methods
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
EP3194406A1 (en) 2014-09-15 2017-07-26 Incyte Holdings Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TW201636351A (en) 2015-02-27 2016-10-16 Incyte Corp And salts of inhibitors are prepared Pi3k
CN107660205A (en) 2015-04-03 2018-02-02 因赛特公司 Heterocyclic Compounds As Lsd1 Inhibitors
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
JP2018527339A (en) 2015-08-12 2018-09-20 インサイト・コーポレイションIncyte Corporation Salt of LSD1 inhibitor
TW201722927A (en) 2015-09-09 2017-07-01 Incyte Corp Pim salts of kinase inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3365340A1 (en) 2015-10-19 2018-08-29 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108472298A (en) 2015-11-24 2018-08-31 深圳阿拉丁医疗科技有限公司 Selective kinase inhibitors
TW201726623A (en) 2015-12-17 2017-08-01 Incyte Corp Examples of the heterocyclic compound of immunomodulators
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
WO2017141104A2 (en) 2016-02-18 2017-08-24 Immune Therapeutics, Inc. Method for inducing a sustained immune response
CN109414410A (en) 2016-04-22 2019-03-01 因赛特公司 The preparation of LSD1 inhibitor
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
JP2019523231A (en) 2016-06-20 2019-08-22 インサイト・コーポレイションIncyte Corporation Heterocyclic compounds as immunomodulators
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
EP3484866A1 (en) 2016-07-14 2019-05-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP3510032A1 (en) 2016-09-09 2019-07-17 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (en) 2016-09-09 2018-04-01 美商英塞特公司 Pyrazolopyrimidine compounds and uses thereof
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN110267953A (en) 2016-12-22 2019-09-20 因赛特公司 Imidazolidine simultaneously [4,5-C] pyridine derivate as PD-L1 internalization inducer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019002571A1 (en) 2017-06-29 2019-01-03 Recordati Industria Chimica E Farmaceutica Spa HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
US20190076401A1 (en) 2017-09-08 2019-03-14 Incyte Corporation Cyanoindazole compounds and uses thereof
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
WO2019084459A1 (en) 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. Crystalline salts of a b-raf kinase inhibitor
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
US20190255053A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
WO2019164846A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US20190256520A1 (en) 2018-02-20 2019-08-22 Incyte Corporation Indazole compounds and uses thereof
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076347A (en) * 1976-07-21 1978-02-28 Dayco Corporation Antifriction nylon member
US4547534A (en) * 1983-03-18 1985-10-15 Memorex Corporation Method to disperse fine solids without size reduction
US4768366A (en) * 1987-04-30 1988-09-06 Tadeusz Sendzimir Wide strip mill using pressure elements
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
GB9726543D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel compositions
WO2000072973A1 (en) * 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition

Also Published As

Publication number Publication date
NO20026120D0 (en) 2002-12-19
WO2002000196A3 (en) 2002-06-27
DE60105023T2 (en) 2005-08-18
PT1294358E (en) 2004-12-31
US20060214037A1 (en) 2006-09-28
ES2225624T3 (en) 2005-03-16
KR20030018013A (en) 2003-03-04
BR0111747A (en) 2003-07-08
TWI290836B (en) 2007-12-11
MY128806A (en) 2007-02-28
WO2002000196A2 (en) 2002-01-03
AU1560802A (en) 2002-01-08
US20040089753A1 (en) 2004-05-13
JP2004501182A (en) 2004-01-15
NZ522783A (en) 2004-07-30
EP1294358B1 (en) 2004-08-18
HK1055242A1 (en) 2005-04-29
HU230396B1 (en) 2016-04-28
DE60105023D1 (en) 2004-09-23
EP1294358A2 (en) 2003-03-26
KR100786927B1 (en) 2007-12-17
PL359065A1 (en) 2004-08-23
IL153231A (en) 2008-06-05
NO20026120L (en) 2003-01-27
PL202623B1 (en) 2009-07-31
CA2413330A1 (en) 2002-01-03
MXPA03000051A (en) 2003-08-19
CN1438876A (en) 2003-08-27
AR029284A1 (en) 2003-06-18
CN1321628C (en) 2007-06-20
SI1294358T1 (en) 2004-12-31
NO333747B1 (en) 2013-09-09
JP4188078B2 (en) 2008-11-26
CZ20024263A3 (en) 2003-06-18
AT273695T (en) 2004-09-15
HU0301583A2 (en) 2003-08-28
CZ303572B6 (en) 2012-12-12
AU2002215608B2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
Bisby et al. Characterization of biodiversity
AU732769C (en) Security cage for game machine and game machine using the same
TWI258462B (en) Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
TWI268781B (en) Stable and taste masked pharmaceutical dosage form using porous apatite grains
TW404840B (en) Fluoxetine pharmaceutical formulations
TW538039B (en) Neutral S-omeprazole in a form or b form, process for preparing the same, and pharmaceutical composition comprising the same
AU757424C (en) Removable food processing tool support system for blenders, food processors, grinders and similar apparatus
HUT74074A (en) New delta-amino-gamma-hydroxy-omega-aryl-alkane-carboxylic-acid-amides, pharmaceutical compns. contg. them and process for preparing the said compds.
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2001085664A8 (en) Compounds and methods for regulating bacterial growth and pathogenesis
CA2154424A1 (en) 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect
EP0843339A3 (en) Processing apparatus
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
WO2001046700A3 (en) Sodium channels as targets for amyloid beta
HRP20010590A2 (en) Triazole compounds and their use
HU0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
ZA200102869B (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents.
BG103003A (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical chelateforming means with a metal
ZA9807540B (en) Process for the preparation of stanol esters, and use thereof.
CA2105552A1 (en) Soluble ligands for cd40
MA26629A1 (en) Pharmaceutical Preparation sildenafil oral disintegrating, and process for its production
YU63202A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
TW510898B (en) Benzothiazole protein tyrosine kinase inhibitors
IL174664D0 (en) Optically active amino alcohol derivatives and processes for the preparation thereof
CA2378574A1 (en) Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-cd20 antibody

Legal Events

Date Code Title Description
FF Patents granted
KB Patents renewed
KB Patents renewed
FF Patents granted